期刊
JOURNAL OF CONTROLLED RELEASE
卷 168, 期 2, 页码 179-199出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2013.03.010
关键词
Cancer vaccines; Immunotherapy; Nanoparticles; Active targeting; Adjuvants
资金
- Fundacao para a Ciencia e Tecnologia
- Ministerio da Ciencia e Tecnologia, Portugal [SFRH/BD/64295/2009, PTDC/SAU-FAR/119389/2010]
- Fonds de la Recherche Scientifique Medicale (Belgium)
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-FAR/119389/2010, SFRH/BD/64295/2009] Funding Source: FCT
The concept of therapeutic cancer vaccines is based on the activation of the immune system against tumor cells after the presentation of tumor antigens. Nanoparticles (NPs) have shown great potential as delivery systems for cancer vaccines as they potentiate the co-delivery of tumor-associated antigens and adjuvants to dendritic cells (DCs), insuring effective activation of the immune system against tumor cells. In this review, the immunological mechanisms behind cancer vaccines, including the role of DCs in the stimulation of T lymphocytes and the use of Toll-like receptor (TLR) ligands as adjuvants will be discussed. An overview of each of the three essential components of a therapeutic cancer vaccine - antigen, adjuvant and delivery system - will be provided with special emphasis on the potential of particulate delivery systems for cancer vaccines, in particular those made of biodegradable aliphatic polyesters, such as poly(lactic-co-glycolic acid) (PLGA) and poly-e-caprolactone (PCL). Some of the factors that can influence NP uptake by DCs, including size, surface charge, surface functionalization and route of administration, will also be considered. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据